VIDAS® - VIDAS® TPSA is a In Vitro Diagnostic kit for the - BIOMERIEUX SA

Duns Number:276816717

Device Description: VIDAS® TPSA is a In Vitro Diagnostic kit for the quantitative detection of total prostate VIDAS® TPSA is a In Vitro Diagnostic kit for the quantitative detection of total prostate specific antigen (PSA) in human serum, using an enzyme immunoassay (EIA) method.

Want to know more about this Product? Request more information now!


More Product Details

Catalog Number

30428-01

Brand Name

VIDAS®

Version/Model Number

TPSA

Device Commercial Distribution Status

Not in Commercial Distribution

Commercial Distribution End Date

March 23, 2017

Issuing Agency

In GS1

Product Characteristics

MRI safety Status

Labeling does not contain MRI Safety Information

Device required to be labeled as containing natural rubber latex or dry natural rubber (21 CFR 801.437)

-

Device labeled as "Not made with natural rubber latex"

-

For Single-Use

-

Prescription Use (Rx)

Yes

Over the Counter (OTC)

-

Kit

-

Combination Product

-

Human Cell, Tissue or Cellular or Tissue-Based Product (HCT/P)

-

FDA Premarket Submission

P040008,P040008,P040008,P040008,P040008,P040008,P040008,P040008,P040008,P040008,P040008

Product Code Details

Product Code

MTF

Product Code Name

Total,Prostate Specific Antigen(Noncomplexed&Complexed) For Detection Of Prostate Cancer

Device Record Status

Public Device Record Key

4bc87b37-a9db-4eed-a982-b7a49be1f361

Public Version Date

February 06, 2020

Public Version Number

4

DI Record Publish Date

September 23, 2014

Additional Identifiers

Package DI Number

None

Quantity per Package

-

Contains DI Package

-

Package Discontinue Date

-

Package Status

-

Package Type

-

"BIOMERIEUX SA" Characteristics
Device Class Device Class Description No of Devices
1 A medical device with low to moderate risk that requires general controls 82
2 A medical device with a moderate to high risk that requires special controls. 156
3 A medical device with high risk that requires premarket approval 3